Similarly, pharmacological SPPL2a blockade can reshape antigen-presenting cell function, although genetic evidence shows that SPPL2a loss in humans leads to dendritic cell and B-cell defects with increased infection risk, highlighting the need for caution [160]. Here, SPPL2A is linked to infection.